戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ed through structure-guided modifications of androgen receptor antagonists.
2 ovides strong rationale for developing novel androgen receptor antagonists.
3 ues were prepared and evaluated as potential androgen receptor antagonists against two human prostate
4                              Apalutamide, an androgen receptor antagonist, and abiraterone acetate pl
5 mide (MDV3100) is a potent second-generation androgen receptor antagonist approved for the treatment
6       Advanced prostate cancers resistant to androgen receptor antagonists are still susceptible to n
7 NP1 was absent with co-administration of the androgen receptor antagonist bicalutamide and in androge
8                    Conversely, flutamide, an androgen receptor antagonist, did not affect androgen st
9 urthermore, in male mice, treatment with the androgen receptor antagonist enzalutamide did not decrea
10                                          The androgen receptor antagonist enzalutamide was associated
11 ed males and those receiving the competitive androgen receptor antagonist flutamide had significantly
12 fically, we bilaterally implanted the potent androgen receptor antagonist flutamide in two key brain
13                                 Finally, the androgen receptor antagonist flutamide inhibited the inc
14  were reversed by in vivo treatment with the androgen receptor antagonist flutamide, suggesting that
15  were divided in five groups (n = 10/group): androgen receptor antagonist (flutamide); estrogen recep
16     Moreover, prenatal administration of the androgen receptor antagonist, flutamide, equalizes devel
17 T4 in vivo and in vitro were reversed by the androgen receptor antagonist, flutamide, indicating that
18 caused by hCG treatment was prevented by the androgen receptor antagonist, flutamide.
19 F-0998425, (-)- 6a] is a novel, nonsteroidal androgen receptor antagonist for sebum control and treat
20 nowledge, DIM is the first example of a pure androgen receptor antagonist from plants.
21                  Treatment with estrogen and androgen receptor antagonists had opposite effects on Le
22 ains androgen-receptor dependent, and potent androgen-receptor antagonists induce tumour regression i
23 ific antigen and objective responses with an androgen receptor antagonist (MDV3100).
24 at mediate a switch in function of selective androgen receptor antagonists/modulators (SARMs) from re
25 osterone was repressed by co-exposure to the androgen receptor antagonist nilutamide supporting a pot
26 d-type mice, co-treatment with flutamide, an androgen receptor antagonist, prevents not only the deve
27                         A novel nonsteroidal androgen receptor antagonist, (R)-4-(1-benzyl-4,4-dimeth
28 lnerability for treatment of next-generation androgen receptor antagonist-resistant prostate cancer b
29 positive outcomes for non-metastatic PC with androgen receptor antagonists, respectively.
30 (gonadotropin-releasing hormone) modulators, androgen receptor antagonists, selective estrogen recept
31        The introduction of second-generation androgen receptor antagonists (SG-ARAs) has greatly impa
32                                              Androgen receptor antagonists showed agonistic activity
33                    The mineralocorticoid and androgen receptor antagonist spironolactone (SP) was rec
34                                MDV3100 is an androgen-receptor antagonist that blocks androgens from
35        Darolutamide is a structurally unique androgen-receptor antagonist that is under development f
36 tate cancer growth alone and in synergy with androgen-receptor antagonist treatment in vivo.
37                                  Several new androgen receptor antagonists were synthesized and found